Sugi Predict

Sugi Predict / Targets / LCK

LCK

Tyrosine-protein kinase Lck · P06239 · LCK on Sugi Atlas →

420,299 patent compounds predicted against LCK, 304,265 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL42089 SCHEMBL42089 0.73 18/20
Piceatannol Piceatannol (SCHEMBL43541) 1.00 6/20
SCHEMBL41400 SCHEMBL41400 0.53 6/20
SCHEMBL46894 SCHEMBL46894 0.51 6/20
SCHEMBL58735 SCHEMBL58735 0.47 6/20
Whi-P131 Whi-P131 (SCHEMBL29295) 0.97 5/20
SCHEMBL58313 SCHEMBL58313 0.59 5/20
SCHEMBL58543 SCHEMBL58543 0.57 5/20
SCHEMBL58496 SCHEMBL58496 0.44 5/20
Nilotinib Nilotinib (SCHEMBL7901) 1.00 4/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL8226) 1.00 4/20
SCHEMBL29651 SCHEMBL29651 0.70 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL8436) 0.63 4/20
SCHEMBL30399 SCHEMBL30399 0.60 4/20
Gentisic Acid Gentisic Acid (SCHEMBL3690) 0.59 4/20
SCHEMBL58550 SCHEMBL58550 0.55 4/20
SCHEMBL41115 SCHEMBL41115 0.53 4/20
SCHEMBL57890 SCHEMBL57890 0.53 4/20
SCHEMBL58732 SCHEMBL58732 0.51 4/20
SCHEMBL58416 SCHEMBL58416 0.50 4/20

Clinical trials — most relevant to LCK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma PHASE2UNKNOWN
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma PHASE2COMPLETED
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma PHASE1/PHASE2UNKNOWN
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection PHASE2NOT_YET_RECRUITING
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer PHASE2COMPLETED
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission PHASE2NOT_YET_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Clinical Study to Evaluate SM17 in Healthy Participants PHASE1COMPLETED
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 nanCOMPLETED
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LCK binder may also engage these)

ProteinNameSimilarity
P06240 — 1.000 P06240 →
Q5PXS1 — 1.000 Q5PXS1 →
Q01621 — 1.000 Q01621 →
P50545 — 1.000 P50545 →
P42683 — 1.000 P42683 →
Q95KR7 — 0.997 Q95KR7 →
HCK Tyrosine-protein kinase HCK 0.997 landscape →
FYN Tyrosine-protein kinase Fyn 0.996 landscape →
Q6EWH2 — 0.995 Q6EWH2 →
LYN Tyrosine-protein kinase Lyn 0.995 landscape →
Q6P6U0 — 0.995 Q6P6U0 →
FGR Tyrosine-protein kinase Fgr 0.995 landscape →
P14234 — 0.994 P14234 →
Q02977 — 0.994 Q02977 →
P39688 — 0.993 P39688 →
P63185 — 0.993 P63185 →
Q62844 — 0.993 Q62844 →
P00525 — 0.993 P00525 →
P13116 — 0.992 P13116 →
P10936 — 0.992 P10936 →
P25911 — 0.992 P25911 →
A1Y2K1 — 0.992 A1Y2K1 →
P25020 — 0.991 P25020 →
P08103 — 0.990 P08103 →
P00527 — 0.990 P00527 →
P00526 — 0.990 P00526 →
P27447 — 0.990 P27447 →
P13115 — 0.989 P13115 →
Q95M30 — 0.989 Q95M30 →
YES1 Tyrosine-protein kinase Yes 0.989 landscape →